牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has received an additional 180-day extension from Nasdaq to meet the Minimum Bid Price Requirement. The extension, granted on January 30, 2024, allows the company until July 29, 2024, to regain compliance with the $1 per share minimum bid price rule. Failure to meet this requirement within the extended period could lead to delisting, although the company would have the right to appeal such a decision. Heart Test Laboratories is considering measures, including a potential reverse stock split, to address the compliance issue. However, there is no certainty that the company will achieve compliance within the new timeframe. This development follows an initial notification from Nasdaq on August 2, 2023, regarding the company's non-compliance based on its stock's closing bid price over the preceding 30 business days.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has received an additional 180-day extension from Nasdaq to meet the Minimum Bid Price Requirement. The extension, granted on January 30, 2024, allows the company until July 29, 2024, to regain compliance with the $1 per share minimum bid price rule. Failure to meet this requirement within the extended period could lead to delisting, although the company would have the right to appeal such a decision. Heart Test Laboratories is considering measures, including a potential reverse stock split, to address the compliance issue. However, there is no certainty that the company will achieve compliance within the new timeframe. This development follows an initial notification from Nasdaq on August 2, 2023, regarding the company's non-compliance based on its stock's closing bid price over the preceding 30 business days.
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 已獲得納斯達克的額外180天延期，以滿足最低出價要求。延期於2024年1月30日批准，允許該公司在2024年7月29日之前重新遵守每股1美元的最低出價規則。在延長的期限內未能滿足這一要求可能會導致退市，儘管該公司有權對此類決定提出上訴。心臟測試實驗室正在考慮採取措施，包括可能的反向股票分割，以解決合規問題。但是，尚不確定該公司是否會在新的時間框架內實現合規。這一事態發展是在納斯達克於2023年8月2日根據其股票在前30個工作日的收盤出價發出初步通知之後發生的，該通知涉及該公司的違規行爲。
在納斯達克股票市場上市的公司Heart Test Laboratories, Inc. 已獲得納斯達克的額外180天延期，以滿足最低出價要求。延期於2024年1月30日批准，允許該公司在2024年7月29日之前重新遵守每股1美元的最低出價規則。在延長的期限內未能滿足這一要求可能會導致退市，儘管該公司有權對此類決定提出上訴。心臟測試實驗室正在考慮採取措施，包括可能的反向股票分割，以解決合規問題。但是，尚不確定該公司是否會在新的時間框架內實現合規。這一事態發展是在納斯達克於2023年8月2日根據其股票在前30個工作日的收盤出價發出初步通知之後發生的，該通知涉及該公司的違規行爲。
有用
沒用